{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T17:23:47Z","timestamp":1764264227063,"version":"3.46.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"name":"Simcere-Medgenn Co., Ltd."},{"name":"Yantai Science and Technology Project"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.ejphar.2014.06.002","type":"journal-article","created":{"date-parts":[[2014,6,11]],"date-time":"2014-06-11T15:34:13Z","timestamp":1402500853000},"page":"722-732","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["GMP production and characterization of leucine zipper-tagged tumor necrosis factor-related apoptosis-inducing ligand (LZ-TRAIL) for phase I clinical trial"],"prefix":"10.1016","volume":"740","author":[{"given":"Jing","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaobin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leixiu","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peipei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangjun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shifu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Honghao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunpeng","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2014.06.002_bib1","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/sj.cdd.4402306","article-title":"Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5","volume":"15","author":"Adams","year":"2008","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.ejphar.2014.06.002_bib2","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1200\/JCO.2007.15.7198","article-title":"Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2\/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L\/TRAIL)","volume":"26","author":"Ashkenazi","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2014.06.002_bib3","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1172\/JCI6926","article-title":"Safety and antitumor activity of recombinant soluble Apo2 ligand","volume":"104","author":"Ashkenazi","year":"1999","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejphar.2014.06.002_bib4","doi-asserted-by":"crossref","first-page":"20632","DOI":"10.1074\/jbc.M909721199","article-title":"Cysteine 230 is essential for the structure and activity of the cytotoxic ligand TRAIL","volume":"275","author":"Bodmer","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2014.06.002_bib5","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1517\/14712598.8.8.1167","article-title":"Apomab: an agonist monoclonal antibody directed against Death Receptor 5\/TRAIL-Receptor 2 for use in the treatment of solid tumors","volume":"8","author":"Camidge","year":"2008","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.ejphar.2014.06.002_bib6","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.biocel.2007.02.007","article-title":"TRAIL signalling: decisions between life and death","volume":"39","author":"Falschlehner","year":"2007","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.ejphar.2014.06.002_bib7","first-page":"13","article-title":"Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5)","volume":"25","author":"Forero-Torres","year":"2010","journal-title":"Cancer Biother. Radiopharm."},{"key":"10.1016\/j.ejphar.2014.06.002_bib8","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1158\/1078-0432.CCR-05-2635","article-title":"Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs","volume":"12","author":"Ganten","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejphar.2014.06.002_bib9","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.2174\/0929867311320170009","article-title":"TRAIL-based therapeutic approaches for the treatment of pediatric malignancies","volume":"20","author":"Gasparini","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejphar.2014.06.002_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2567.2005.02143.x","article-title":"The intriguing biology of the tumour necrosis factor\/tumour necrosis factor receptor superfamily: players, rules and the games","volume":"115","author":"Hehlgans","year":"2005","journal-title":"Immunology"},{"key":"10.1016\/j.ejphar.2014.06.002_bib11","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1200\/JCO.2009.25.1991","article-title":"Phase I dose-escalation study of recombinant human Apo2L\/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer","volume":"28","author":"Herbst","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2014.06.002_bib12","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1158\/1078-0432.CCR-07-1416","article-title":"A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies","volume":"14","author":"Hotte","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejphar.2014.06.002_bib13","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/75045","article-title":"Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand","volume":"6","author":"Jo","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2014.06.002_bib14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0022-3565(24)29298-3","article-title":"Preclinical studies to predict the disposition of Apo2L\/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety","volume":"299","author":"Kelley","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2014.06.002_bib15","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jconrel.2012.07.021","article-title":"PEG-transferrin conjugated TRAIL (TNF-related apoptosis-inducing ligand) for therapeutic tumor targeting","volume":"162","author":"Kim","year":"2012","journal-title":"J. Control Release"},{"key":"10.1016\/j.ejphar.2014.06.002_bib16","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1021\/bc200187k","article-title":"PEGylated TNF-related apoptosis-inducing ligand (TRAIL) analogues: pharmacokinetics and antitumor effects","volume":"22","author":"Kim","year":"2011","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.ejphar.2014.06.002_bib17","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/86397","article-title":"Differential hepatocyte toxicity of recombinant Apo2L\/TRAIL versions","volume":"7","author":"Lawrence","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2014.06.002_bib18","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2003.12332.x","article-title":"TRAIL-induced apoptosis and gene induction in HaCaT keratinocytes: differential contribution of TRAIL receptors 1 and 2","volume":"121","author":"Leverkus","year":"2003","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.ejphar.2014.06.002_bib19","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.2174\/138945011798829357","article-title":"Targeting TRAIL towards the clinic","volume":"12","author":"Mahalingam","year":"2011","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.ejphar.2014.06.002_bib20","doi-asserted-by":"crossref","first-page":"4141","DOI":"10.1200\/JCO.2012.44.1055","article-title":"Phase I trial and pharmacokinetic study of lexatumumab in pediatric patients with solid tumors","volume":"30","author":"Merchant","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2014.06.002_bib21","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/nrc1893","article-title":"Drug penetration in solid tumours","volume":"6","author":"Minchinton","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejphar.2014.06.002_bib22","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.bbrc.2010.04.134","article-title":"Superior serum half life of albumin tagged TNF ligands","volume":"396","author":"Muller","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejphar.2014.06.002_bib23","doi-asserted-by":"crossref","first-page":"12687","DOI":"10.1074\/jbc.271.22.12687","article-title":"Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family","volume":"271","author":"Pitti","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2014.06.002_bib24","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/sj.leu.2402338","article-title":"TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors","volume":"16","author":"Plasilova","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.ejphar.2014.06.002_bib25","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/86401","article-title":"Avoiding premature apoptosis of normal epidermal cells","volume":"7","author":"Qin","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2014.06.002_bib26","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1158\/1535-7163.MCT-09-0202","article-title":"Engineering a leucine zipper-TRAIL homotrimer with improved cytotoxicity in tumor cells","volume":"8","author":"Rozanov","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejphar.2014.06.002_bib27","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1200\/JCO.2011.37.2623","article-title":"Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer","volume":"29","author":"Soria","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2014.06.002_bib28","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.molmed.2013.08.007","article-title":"TRAIL on trial: preclinical advances in cancer therapy","volume":"19","author":"Stuckey","year":"2013","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.ejphar.2014.06.002_bib29","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cellsig.2003.08.007","article-title":"Death receptor-induced cell killing","volume":"16","author":"Thorburn","year":"2004","journal-title":"Cell Signal"},{"key":"10.1016\/j.ejphar.2014.06.002_bib30","doi-asserted-by":"crossref","first-page":"21265","DOI":"10.1074\/jbc.M111.306480","article-title":"Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces death receptor 5 networks that are highly organized","volume":"287","author":"Valley","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2014.06.002_bib31","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/annonc\/mdp292","article-title":"Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors","volume":"21","author":"Wakelee","year":"2010","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejphar.2014.06.002_bib32","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/5517","article-title":"Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo","volume":"5","author":"Walczak","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2014.06.002_bib33","article-title":"Immunoglobulin Fc domain fusion to TRAIL significantly prolongs its plasma half-life and enhances its anti-tumor activity","author":"Wang","year":"2014","journal-title":"Mol. Cancer Ther"},{"key":"10.1016\/j.ejphar.2014.06.002_bib34","doi-asserted-by":"crossref","first-page":"6207","DOI":"10.1038\/onc.2008.298","article-title":"The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway","volume":"27","author":"Wang","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.ejphar.2014.06.002_bib35","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/1074-7613(95)90057-8","article-title":"Identification and characterization of a new member of the TNF family that induces apoptosis","volume":"3","author":"Wiley","year":"1995","journal-title":"Immunity"},{"key":"10.1016\/j.ejphar.2014.06.002_bib36","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s10529-006-9300-7","article-title":"Biological and physicochemical evaluation of the conformational stability of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)","volume":"29","author":"Youn","year":"2007","journal-title":"Biotechnol. Lett."},{"key":"10.1016\/j.ejphar.2014.06.002_bib37","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1038\/sj.bjc.6605987","article-title":"A Phase 1b\/2 trial of mapatumumab in patients with relapsed\/refractory non-Hodgkin\u05f3s lymphoma","volume":"103","author":"Younes","year":"2010","journal-title":"Br. J. Cancer"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299914004415?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299914004415?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T17:19:22Z","timestamp":1764263962000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299914004415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":37,"alternative-id":["S0014299914004415"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2014.06.002","relation":{},"ISSN":["0014-2999"],"issn-type":[{"type":"print","value":"0014-2999"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GMP production and characterization of leucine zipper-tagged tumor necrosis factor-related apoptosis-inducing ligand (LZ-TRAIL) for phase I clinical trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2014.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}